These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15571288)

  • 21. Inhibition of protein kinase C activator-mediated induction of p21CIP1 and p27KIP1 by deoxycytidine analogs in human leukemia cells: relationship to apoptosis and differentiation.
    Vrana JA; Kramer LB; Saunders AM; Zhang XF; Dent P; Povirk LF; Grant S
    Biochem Pharmacol; 1999 Jul; 58(1):121-31. PubMed ID: 10403525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimetabolites.
    Grem JL; Takimoto CH; Multani P; Chu E; Ryan D; Chabner BA; Allegra CJ; Johnston PG
    Cancer Chemother Biol Response Modif; 1999; 18():1-38. PubMed ID: 10800475
    [No Abstract]   [Full Text] [Related]  

  • 23. In vitro study of the combination gemcitabine + fludarabine on freshly isolated chronic lymphocytic leukemia cells.
    Tosi P; Pellacani A; Zinzani PL; Magagnoli M; Visani G; Tura S
    Haematologica; 1999 Sep; 84(9):794-8. PubMed ID: 10477451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IMP-GMP specific cytosolic 5'-nucleotidase regulates nucleotide pool and prodrug metabolism.
    Cividini F; Filoni DN; Pesi R; Allegrini S; Camici M; Tozzi MG
    Biochim Biophys Acta; 2015 Jul; 1850(7):1354-61. PubMed ID: 25857773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells.
    Bouffard DY; Momparler LF; Momparler RL
    Anticancer Drugs; 1991 Feb; 2(1):49-55. PubMed ID: 1958852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review).
    Van den Neste E; Cardoen S; Offner F; Bontemps F
    Int J Oncol; 2005 Oct; 27(4):1113-24. PubMed ID: 16142330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells.
    Takemura H; Urasaki Y; Yoshida A; Fukushima T; Ueda T
    Cancer Res; 2001 Jan; 61(1):172-7. PubMed ID: 11196156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine.
    Neff T; Blau CA
    Exp Hematol; 1996 Sep; 24(11):1340-6. PubMed ID: 8862446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs.
    Niitsu N; Umeda M; Honma Y
    Leuk Res; 2000 Jan; 24(1):1-9. PubMed ID: 10634639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinosylcytosine (ara-C) in leukemia and solid tumor cell lines.
    Bergman AM; Kuiper CM; Myhren F; Sandvold ML; Hendriks HR; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1523-6. PubMed ID: 15571290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular resistance against troxacitabine in human cell lines and pediatric patient acute myeloid leukemia blast cells.
    Adema AD; Zuurbier L; Floor K; Hubeek I; Kaspers GJ; Albertoni F; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2006; 25(9-11):981-6. PubMed ID: 17065050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro assessment of nucleoside analogs in multiple myeloma.
    Krett NL; Ayres M; Nabhan C; Ma C; Nowak B; Nawrocki S; Rosen ST; Gandhi V
    Cancer Chemother Pharmacol; 2004 Aug; 54(2):113-21. PubMed ID: 15133625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consequences of 2',2'-difluorodeoxycytidine (gemcitabine) on replicative DNA synthesis in intact HL-60 cells.
    Ross DD; Cuddy DP
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):26-34. PubMed ID: 7481841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia.
    Hubeek I; Peters GJ; Broekhuizen AJ; Sargent J; Gibson BE; Creutzig U; Kaspers GJ
    Br J Haematol; 2005 Oct; 131(2):219-22. PubMed ID: 16197453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of resistance to the lipophilic cytarabine prodrug elacytarabine (CP-4055) in CEM leukemic cells.
    Adema AD; Losekoot N; Smid K; Kathmann I; Myhren F; Sandvold ML; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):394-9. PubMed ID: 20544525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue.
    Galmarini CM; Clarke ML; Santos CL; Jordheim L; Perigaud C; Gosselin G; Cros E; Mackey JR; Dumontet C
    Int J Cancer; 2003 Oct; 107(1):149-54. PubMed ID: 12925971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems.
    King KM; Damaraju VL; Vickers MF; Yao SY; Lang T; Tackaberry TE; Mowles DA; Ng AM; Young JD; Cass CE
    Mol Pharmacol; 2006 Jan; 69(1):346-53. PubMed ID: 16234483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell specific cytotoxicity and structure-activity relationship of lipophilic 1-B-D-arabinofuranosylcytosine (ara-C) derivatives.
    Peters GJ; Voorn DA; Kuiper CM; van der Wilt CL; Noordhuis P; Smid K; Myhren F; Sandvold M; Hendriks HR
    Nucleosides Nucleotides; 1999; 18(4-5):877-8. PubMed ID: 10432699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
    Avramis IA; Laug WE; Sausville EA; Avramis VI
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562.
    Dumontet C; Fabianowska-Majewska K; Mantincic D; Callet Bauchu E; Tigaud I; Gandhi V; Lepoivre M; Peters GJ; Rolland MO; Wyczechowska D; Fang X; Gazzo S; Voorn DA; Vanier-Viornery A; MacKey J
    Br J Haematol; 1999 Jul; 106(1):78-85. PubMed ID: 10444166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.